Hi ZThis is a reply to your last post. (Reply function is...

Hi Z

This is a reply to your last post. (Reply function is glitching for me - again!!!)

You ask a fair question. I think it's the ARCUS tech solving the problem - but I could be wrong. I am an optimist by nature - but I have read areference somewhere to the components of the gene editing that were specifically intended to prevent G vs H issues. I will add it to my "find again" list

Precision will have emphasised the lack of G vs H disease in their reporting and announcements because the FDA Guidelines - helpfully just referenced by friend @Fibber require them to be very conscious of the possibility and to have rigorous reporting of same:

"In addition, a major concern for recipients of allogenic CAR T cells is GVHD. Clinical monitoring should include plans to collect information regarding the symptoms and signs of GVHD. A grading system used to assess GVHD (Ref. 48) and a corresponding management algorithm should be included in the clinical protocol. Furthermore, DLT and study stopping rules should incorporate GVHD.15 "
Source: p. 33 of https://www.fda.gov/media/156896/download

Also, of course, because they will know that many intelligent and informed readers will be aware of G vs H risks and therefore keenly interested in Graft vs Host outcomes. As indeed you are!

Cheers

Dave